CaixaBank's 3Q Profit Boosted by Higher Lending Income
By Giulia Petroni
CaixaBank reported a rise in third-quarter profit on higher lending income despite a decline in its loans portfolio.
The Spanish bank on Friday said that net profit was 1.52 billion euros ($1.61 billion) in the three months ended in September, up 19% compared with the same period a year earlier.
Net interest income--the difference between how much a bank earns on clients' loans and how much it pays clients for their deposits--increased 12% on year to EUR2.74 billion in the quarter.
"The bank's performance in the first nine months of this year has been very positive," said Chief Executive Gonzalo Gortazar. "In the context of interest rate normalization, our results are solid, a consequence of good commercial dynamics and prudent credit risk management."
CaixaBank said the common equity tier 1 ratio stood at 12.3% in September, well above regulatory requirements. The return on tangible equity--a key measure of profitability--was 14.1% in the first nine months of the year.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
October 27, 2023 01:54 ET (05:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks